These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 17014481)

  • 1. Treatment of cutaneous T-cell lymphoma with retinoids.
    Zhang C; Duvic M
    Dermatol Ther; 2006; 19(5):264-71. PubMed ID: 17014481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma.
    Zhang C; Duvic M
    Dermatol Ther; 2003; 16(4):322-30. PubMed ID: 14686975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
    Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM
    J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids.
    Stadler R; Kremer A
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S7-10. PubMed ID: 16516669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
    Guitart J
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S17-20. PubMed ID: 16516671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
    Martin AG
    J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The optimal use of bexarotene in cutaneous T-cell lymphoma.
    Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
    Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma.
    Kempf W; Kettelhack N; Duvic M; Burg G
    Hematol Oncol Clin North Am; 2003 Dec; 17(6):1405-19. PubMed ID: 14710892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL).
    Burg G; Dummer R
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S41-4. PubMed ID: 11707863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of cutaneous T cell lymphoma: current status and future directions.
    Apisarnthanarax N; Talpur R; Duvic M
    Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of phototherapy in cutaneous T-cell lymphoma.
    Pothiawala SZ; Baldwin BT; Cherpelis BS; Lien MH; Fenske NA
    J Drugs Dermatol; 2010 Jul; 9(7):764-72. PubMed ID: 20677530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP; Levitan D; Fleischer AB
    J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choices in the treatment of cutaneous T-cell lymphoma.
    Hymes KB
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):18-23. PubMed ID: 17474355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
    Duvic M
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral retinoids and rexinoids in cutaneous T-cell lymphomas.
    Sokołowska-Wojdyło M; Lugowska-Umer H; Maciejewska-Radomska A
    Postepy Dermatol Alergol; 2013 Feb; 30(1):19-29. PubMed ID: 24278042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. About the cutaneous targets of bexarotene in CTCL patients.
    Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
    Exp Dermatol; 2010 Aug; 19(8):e299-301. PubMed ID: 19845753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; He K; Sridhara R; Abraham S; Booth BP; Verbois L; Morse DE; Jee JM; Pope S; Harapanhalli RS; Dagher R; Farrell A; Justice R; Pazdur R
    Clin Cancer Res; 2007 Apr; 13(8):2318-22. PubMed ID: 17438089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on treatment of cutaneous T-cell lymphoma.
    Gardner JM; Evans KG; Musiek A; Rook AH; Kim EJ
    Curr Opin Oncol; 2009 Mar; 21(2):131-7. PubMed ID: 19532014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bexarotene: new preparation. Cutaneous lymphoma: too many adverse effects.
    Prescrire Int; 2004 Jun; 13(71):94-7. PubMed ID: 15233146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.